What is De Novo Software?
De Novo Software is a prominent provider of advanced flow cytometry analysis software, with its flagship product, FCS Express, serving as a comprehensive platform for data analysis, statistics, graphing, and reporting. The company's solutions are critical for a wide array of users, including academic institutions, clinical diagnostic laboratories, and researchers in the burgeoning cell and gene therapy sector. FCS Express is engineered for user-friendliness, adopting a familiar interface akin to Microsoft Office applications to streamline adoption and enhance workflow automation. This focus on intuitive design, coupled with robust analytical capabilities, has cemented De Novo Software's reputation for delivering powerful yet accessible tools for complex biological data interpretation.
How much funding has De Novo Software raised?
De Novo Software has raised a total of $855K across 2 funding rounds:
Debt
$350K
Debt
$505K
Debt (2020): $350K with participation from PPP
Debt (2021): $505K led by PPP
What's next for De Novo Software?
The recent major strategic investment signals a pivotal growth phase for De Novo Software, likely enabling further development of its FCS Express platform and expansion into new market segments. This capital infusion is expected to bolster its competitive edge in the cytometry software landscape, potentially facilitating enhanced data visualization features, AI-driven analytical modules, or broader integration capabilities with other laboratory information systems. The company's focus on supporting critical research areas like cell and gene therapy suggests a strategic alignment with high-growth sectors within biotechnology and healthcare.
See full De Novo Software company page
